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Advances in Molecular 
Subclassification of Colorectal 
Cancer
Avani Athauda and Ian Chau
Abstract
This chapter will highlight the advances made in our understanding of the 
molecular landscape of colorectal cancer (CRC) via the development of molecular 
subclassification systems and their potential predictive and prognostic utility. 
Firstly, the comprehensive integrative analysis of 224 colorectal cancer samples per-
formed by The Cancer Genome Atlas (TCGA) Research Network will be described 
highlighting the potential therapeutic targets identified. The development of 
molecular subclassification systems primarily via gene expression profile analysis 
by independent groups will also be described, and their potential clinical and prog-
nostic associations will also be discussed. The chapter will then go on to describe the 
four consensus molecular subtypes of colorectal cancer which were proposed by an 
international consortium who applied unsupervised clustering techniques to the 
independent classification systems previously described. The clinical and prognos-
tic associations of these four subtypes have been explored, and these findings will 
be discussed. Finally, the utility of molecular subclassification in colorectal cancer 
will be briefly explored.
Keywords: molecular subclassification, consensus molecular subtypes,  
gene expression profiles, colorectal cancer
1. Introduction
Colorectal cancer (CRC) was one of the earliest molecularly characterised solid 
tumours. Vogelstein et al. initially described the stepwise manner of adenoma 
formation to carcinoma via the accumulation of genetic and epigenetic events in the 
late 1980s [1]. This model provided insight into how driver alterations in the main 
oncogenes (KRAS, NRAS, BRAF and PI3K) and tumour suppressor genes (APC, 
TP53 and PTEN) were implicated in the biology of CRC [2]. The accumulation of 
these genetic mutations leads to carcinogenesis through deregulation of key path-
ways involved in cell proliferation, differentiation and apoptosis. It is now known 
that abnormalities of the Wnt signalling pathway are almost ubiquitous in sporadic 
CRC and usually arise from mutations of the APC gene [3].
Further to this, genetic and epigenetic exploration of CRC subsequently 
identified significant molecular heterogeneity in this disease. This was clinically 
evident by the differing responses to systemic therapy and varying clinical course 
of patients with the same stage of tumour. Biomarker discovery in CRC has arisen 
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through the analysis of responders and nonresponders to targeted agents and the 
subsequent discovery of RAS mutations conferring resistance to anti-epidermal 
growth factor receptor (EGFR) therapies. More recently, our deeper understanding 
of the underlying biology of CRC has also revealed that clonal, stromal and immune 
characteristics of tumours are important when considering therapeutic targets. The 
ongoing need to accurately define molecularly distinct subgroups and identify the 
underlying genetic drivers as well as novel therapeutic targets within each subgroup 
in order to rationalise drug development continues to be of paramount importance 
in CRC.
2. Early molecular characterisation of colorectal cancer
It is now well established that the majority of sporadic CRC cases (85%) exhibit 
chromosomal instability (CIN) with changes in chromosome number and structure 
such as deletions, gains, translocations and amplifications. CIN is associated with 
inactivating mutations or losses in the APC tumour suppressor gene which occurs 
early in the adenoma-carcinoma sequence [3]. The remaining 15% of sporadic CRCs 
demonstrate microsatellite instability (MSI) through changes in the number of 
repeats or length of microsatellites. MSI arises through defective DNA mismatch 
repair (MMR) mechanisms caused by epigenetic silencing of the MLH1 gene by 
promotor hypermethylation [4]. Epigenomic studies have shown that MSI tumours 
have a high CpG island methylator phenotype (CIMP-H) which involves aberrant 
methylation of CpG-rich gene promoter regions. This leads to silencing of expres-
sion of critical tumour suppressor genes such as MLH1, thereby leading to the 
development of CRC [5]. Familial syndromes, such as Lynch syndrome/hereditary 
non-polyposis colorectal cancer syndrome (HNPCC), occur through germline 
mutational inactivation of genes encoding MMR proteins, namely, MLH1, MSH2, 
PMS2 and MSH6.
Clinicopathological features and the mutational status of CRC tumours differ 
according to the above classification. Sporadic MSI-high (MSI-H) tumours are more 
likely to be right-sided (proximal), poorly differentiated, mucinous and associated 
with tumour-infiltrating lymphocytes (TILs) and have higher rates of BRAF muta-
tion, whereas microsatellite-stable (MSS) tumours are more frequently left-sided 
(distal) and have higher rates of KRAS mutation [5].
It has been shown that MSI status has both a prognostic and a predictive role 
in CRC. MSI-H tumours have better stage-adjusted survival (in stages I–III) when 
treated with surgery alone and do not derive as much benefit from adjuvant fluo-
rouracil-based chemotherapy as MSS tumours do [4]. In advanced disease, MSI-H 
tumours are associated with a worse prognosis, and this is due to their association 
with activating BRAF mutations [6]. It has more recently been shown that MSI sta-
tus also predicts for significant response and benefit from anti-PD1 antibodies with 
MMR-deficient tumours exhibiting higher response rates and longer progression-
free survival (PFS) than MMR-proficient tumours [7].
3. Integrative molecular analysis of colorectal cancer
It is clear that anatomical factors and common DNA alterations are helpful 
in identifying subtype characteristics in CRC, but they alone are inadequate to 
define the boundaries between the different molecular entities that comprise 
CRC. In recent years, many studies have begun to exploit microarray technology to 
investigate gene expression profiles (GEPs) in CRC; however, no single signature 
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has proven clinically meaningful, especially in regard to predicting prognosis, and 
studies have been poorly reproducible due to the high molecular heterogeneity that 
exists in this disease.
In 2012, The Cancer Genome Atlas (TCGA) Research Network produced a com-
prehensive integrative analysis of 224 colorectal cancer tumour samples with paired 
normal samples in order to improve our understanding of the biology of this disease 
and identify potential therapeutic targets [8]. In addition, independent scientific 
groups also attempted to define intrinsic subtypes of CRC using GEPs in the hope 
that this will refine the molecular classification of CRC and facilitate clinical trans-
lation [9–14]. The findings of all of these independent analyses are discussed below.
3.1 The Cancer Genome Atlas (TCGA) comprehensive analysis of  
colorectal cancer
The comprehensive analysis of CRC undertaken by TCGA Research Network 
included tumours whose clinical and pathological characteristics reflected the 
usual breadth of features of CRC patients. Tumours were split into two main 
groups by mutation rate: those that were hypermutated (16%) and those that were 
non-hypermutated (84%) which seems to match the previously described MSI and 
CIN groups. The hypermutated group was then subdivided into those caused by 
defective MMR (dMMR) with a mutation rate of 12–40 mutations/Mb (approxi-
mately 13%) and those with an extremely high mutation rate of >40 mutations/Mb 
(approximately 3%)—the ultramutated group.
Initially, TCGA researchers considered colon and rectal tumours as separate 
entities due to their known anatomical and therapeutic differences. However, it was 
found that similar patterns of genomic alteration (copy number, expression profile, 
DNA methylation and miRNA changes) were seen in both types of tumours, so they 
were subsequently analysed together within the non-hypermutated group.
Thirty-two genes were identified to be recurrently mutated, and, after removal 
of non-expressed genes, the hypermutated and non-hypermutated groups had 15 
and 17 recurrently mutated genes, respectively (see Table 1).
It was found that the tumour suppressor genes ATM and ARID1A displayed a 
disproportionately high number of frameshift or nonsense mutations. As expected, 
KRAS and NRAS mutations were activating oncogenic mutations at codons 12, 13 
or 61, whereas the other genes had inactivating mutations. BRAF mutations were 
the classical V600E-activating mutations [8]. Given the differences in recurrently 
Hypermutated group Non-hypermutated group
ACVR2A (63%) CASP8 (29%) APC (81%) TCF7L2 (9%)
APC (51%) CDC27 (29%) TP53 (60%) FAM123B (7%)
TGFBR2 (51%) FZD3 (29%) KRAS (43%) SMAD2 (6%)
BRAF (46%) MIER3 (29%) TTN (31%) CTNNB1 (5%)
MSH3 (40%) TCERG1 (29%) PIK3CA (18%) KIAA1804 (4%)
MSH6 (40%) MAP7 (26%) FBXW7 (11%) SOX9 (4%)
MYOB1 (31%) PTPN12 (26%) SMAD4 (10%) ACVR1B (4%)
TCF7L2 (31%) NRAS (9%) GP6C (4%)
EDNRB (3%)
Table 1. 
Significantly mutated genes in non-hypermutated and hypermutated groups.
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mutated genes between hypermutated and non-hypermutated cancers, it appears 
that these tumours progress through different sequences of genetic events.
Interestingly, the recent data published by Jones et al. has identified that non-
V600 BRAF-mutated advanced CRC represents a molecular subtype with distinct 
characteristics (which are different to BRAFV600E-mutated CRC) and an excel-
lent prognosis [15]. These patients may not require the aggressive chemotherapy 
treatment that is beneficial to classical BRAF-mutated patients. It is not yet clear 
whether non-V600 BRAF-mutated cancers harbour the same resistance to anti-
EGFR therapies as cancers with BRAFV600E mutations, but higher frequency of 
concomitant RAS mutations in this subgroup will have to be taken into account.
TCGA analysis provided further confirmation on the pathways previously 
known to be deregulated in CRC. The vast majority of tumours in both groups 
(93% of non-hypermutated and 97% of mutated tumours) had deregulated Wnt 
signalling, predominantly via inactivation of APC. The MAPK signalling pathway 
was also commonly activated, as was the PI3K signalling pathway. Inactivation 
of the TGF-β inhibitory pathway was also seen, resulting in increased activity of 
MYC. Almost all of the analysed tumours, irrespective of location or mutation 
levels, exhibited changes in MYC transcriptional targets, highlighting the important 
role of MYC in CRC development. New findings identified by TCGA included 
recurrent mutations in FAM123B, ARID1A and SOX9 and very high levels of 
overexpression of the Wnt ligand-receptor gene FZD10. The SOX9 gene is associ-
ated with intestinal stem cell differentiation and has not previously been shown to 
be implicated in CRC. It has been shown to facilitate β-catenin degradation [16], 
and its transcription is suppressed by Wnt signalling which is activated by extrinsic 
Wnt ligands. These findings suggest a number of potential therapeutic targets in 
CRC, namely, Wnt signalling inhibitors and small molecule β-catenin inhibitors, 
which are beginning to show initial promise [17–19]. In addition, overexpression 
of the genes ERBB2 and IGF2, which are involved in regulating cell proliferation, 
were identified thus indicating potential therapeutic opportunities of inhibiting the 
products of these genes.
mRNA expression profiles of a subset of 189 TCGA samples separated the 
colorectal tumours into three clusters. One significantly overlapped with CIMP-H 
tumours and was enriched for hypermutated tumours, thereby representing a MSI/
CIMP subgroup. The two other groups were representative of a CIN and an invasive 
phenotype subgroup.
3.2 Intrinsic subtypes of colorectal cancer identified by independent groups
Three molecular CRC subtypes were also identified by Roepman and colleagues 
((A) MMR-deficient epithelial, (B) proliferative epithelial and (C) mesenchymal) 
using unsupervised clustering of whole genome data from 188 CRC tumour samples 
[9]. These intrinsic subtypes were subsequently validated in a cohort of 543 patients 
with stage II–III disease. In addition to identifying these subtypes with phenotypes 
matching those identified via TCGA, prognostic features and chemotherapy benefit 
characteristics were also investigated in this study. The dMMR subtype A (22%) 
was found to be epithelial-like and displayed a strong MSI phenotype linked to 
dMMR and a high mutational rate including activating BRAF mutations. Type A 
patients exhibited the best prognosis with minimal benefit from adjuvant 5-FU 
chemotherapy. The mesenchymal subtype C (16%) tumours exhibit epithelial-to-
mesenchymal transition and show dMMR characteristics. These patients showed a 
poor baseline prognosis and no benefit from adjuvant 5-FU chemotherapy which is 
probably linked to their mesenchymal phenotype and low proliferative activity. The 
proliferative epithelial subtype B (62%) is almost exclusively MSS, BRAF wild type 
5Advances in Molecular Subclassification of Colorectal Cancer
DOI: http://dx.doi.org/10.5772/intechopen.80679
and MMR proficient. They exhibit a relatively poor baseline prognosis but receive 
the most benefit from adjuvant chemotherapy. This study focused on stages II and 
III CRC; therefore, further validation of the subtype classification and its clinical 
relevance on a larger set of stage IV tumours is warranted.
In addition, De Sousa E Melo and colleagues also identified three similar sub-
types using over 1100 CRC tumour samples: chromosomal instable (subtype A), 
microsatellite instable (subtype B) and a third subtype (subtype C) which is largely 
microsatellite stable and contains relatively more CIMP-H carcinomas but cannot 
be identified on the basis of characteristic mutations [10]. This third subtype is 
therefore similar to the third subtype described in the studies above. This subtype 
was found to be associated with a very unfavourable prognosis as well as resistance to 
anti-EGFR targeted therapy. It is thought to relate to sessile-serrated adenomas due 
to a very similar GEP involving upregulation of genes involved in matrix remodelling 
and epithelial-mesenchymal transition (EMT) which was seen in both. This study 
therefore suggests that sessile-serrated adenomas and tumours belonging to subtype 
C possess high malignant potential and need to be clinically managed as such [10].
Further groups have also used GEPs to identify more than three intrinsic subtypes 
of CRC using large numbers of tumour samples. The biological relevance of the 
subtypes has been investigated in regard to treatment response and prognosis. Marisa 
and colleagues utilised a large multicentre cohort of tumour samples from patients 
with stage I–IV CRC, of which 556 fulfilled RNA quality requirements for GEP analy-
sis [11]. These samples were split into a discovery set (n = 443) and a validation set 
(n = 1029) which also included 906 samples from eight public datasets. Unsupervised 
hierarchical clustering was applied to gene expression data which form the discovery 
subset to identify six molecular subtypes (C1–C6) with distinct clinicopathological 
features, molecular alterations, enrichments of supervised gene expression signatures 
and deregulated signalling pathways. In addition to identifying a deficient MMR 
subtype (C2), three CIN subtypes were shown (C1, C5 and C6): one with downregu-
lated immune pathways (C1), one with upregulation of Wnt pathway (C5) and one 
displaying a normal-like GEP (C6). The remaining two were comprised of a KRAS 
mutant subtype (C3) and a cancer stem cell subtype (C4).
As expected, BRAF mutation was associated with the C2 subtype but was also 
frequent in the C4 CIMP-H, poor prognosis subtype. Although TP53 and KRAS 
mutations were found in all subtypes, the C3 subtype was highly enriched for KRAS 
mutant tumours suggesting a specific role for this mutation in this subtype of CRC. The 
biological relevance of these six subtypes is highlighted by their differing prognoses 
with the C4 and C6 subtypes being independently associated with the shortest relapse-
free survival (RFS). However, the robustness of this gene signature as a prognostic 
classification requires further confirmation as some established prognostic factors in 
CRC, such as tumour grade and number of nodes examined, were not available for a 
significant proportion of cases and thus were not included in the analysis.
Schlicker et al. performed genome-wide mRNA expression profiling on 62 pri-
mary CRC samples using an unsupervised iterative approach [12]. Two main groups 
were identified (type 1 mesenchymal and type 2 epithelial) which were then split 
into five subtypes which were validated in independent published datasets compris-
ing over 1600 samples. This subtype stratification was successfully aligned to several 
CRC cell line panels, and it was found that the GEPs defining the subtypes were well 
represented in these cell lines. Pharmacological response data showed that type 2 cell 
lines were more sensitive to treatment with aurora kinase inhibitors in keeping with 
the high levels of expression of aurora kinase A seen in the samples of this subtype. 
Additional data suggested that subtype 1.2 cell lines were most sensitive to inhibi-
tion of Src and also showed a higher sensitivity to inhibition of proteins on the PI3K 
pathway, GSK3β, PI3K and TOR than subtype 2.1 [12].
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Budinska et al. performed unsupervised clustering of 1113 CRC samples based 
on gene models and distinguished at least five different gene expression CRC 
subtypes which they called surface crypt-like (A), lower crypt-like (B), CIMP-H-
like (C), mesenchymal (D) and mixed (E) [13]. These subtypes showed distinct 
biological motifs and morphological features as well as differences in prognosis. The 
subtypes were validated in an independent dataset of 720 CRC expression profiles. 
Subtype C was enriched for both MSI and BRAF mutations, and its characteristics 
were in keeping with the described CIMP-H phenotype and hypermutated tumours 
found in TCGA analysis. This subtype had one of the best outcomes for RFS but the 
worst outcome in survival after relapse (SAR). Once again, KRAS mutations were 
found in all subtypes, and this supports the emerging theory that KRAS mutant 
CRCs are highly heterogeneous and that the oncogenic role of KRAS varies with 
the specific mutation and molecular background of the tumour in which it occurs 
[20]. Subtypes C and D were associated with the worst overall survival (OS)—for 
subtype D this was primarily due to early relapse associated with high EMT gene 
expression and low proliferation-associated gene expression, and for subtype C, it 
was the result of short SAR.
Subtypes B and E highly expressed canonical Wnt signalling target signatures, 
whereas subtypes A and D and normal samples expressed low levels of this 
signature. This was in concordance with the corresponding high percentages of 
β-catenin-positive nuclei seen in subtypes B and E and converse low percentages 
seen in subtypes A and D. This analysis is in support of the data suggesting that 
the colon stem cell signature, under the condition of silenced canonical Wnt target 
genes, is associated with a higher risk of recurrence (subtype D) [21].
Sadanandam and colleagues performed an analysis of GEPs from 1290 CRC 
samples using consensus-based unsupervised clustering. The resultant clusters 
were then correlated with response to cetuximab using a dataset annotated with 
therapeutic response to cetuximab in 80 patients [14]. The results of these studies 
identified five clinically relevant CRC subtypes which were named according to 
genes preferentially expressed in each. The transit-amplifying subgroup was found 
to contain two groups which differed in cetuximab sensitivity, so it was split into 
cetuximab-sensitive and cetuximab-resistant, thereby making six subgroups in 
total. These sub-subtypes showed the best response to cetuximab and increased 
sensitivity to cMET inhibition, respectively.
Additionally, response to standard chemotherapy with FOLFIRI (5-FU and 
irinotecan) was also investigated, and the analyses suggested that stem-like subtype 
tumours, both in the adjuvant and metastatic settings, and inflammatory-subtype 
tumours in the adjuvant setting may best be treated with FOLFIRI [14]. The transit-
amplifying sub-subtypes and the goblet-like subtype were not likely to respond to 
FOLFIRI in the adjuvant setting, thereby potentially sparing some patients from 
toxicity of futile treatment. These findings obviously warrant further retrospective 
and prospective validation, but in unselected CRC patients, FOLFIRI chemotherapy 
has not shown a survival benefit in the adjuvant setting.
3.3 Outcomes of integrative molecular analysis in CRC
As is evidenced above, up to six molecular subtypes of CRC have been identified by 
these independent groups, but only superficial similarities exist between the studies. 
The main characteristics of these subtypes are summarised in Table 2. Two subtypes 
have been repeatedly identified (microsatellite instability enriched and high expression 
of mesenchymal genes), but full consistency amongst the others has not been achieved 
probably due to the underlying biological complexity of this cancer and the significant 
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Subtype Major subtype 
category
Subtype characteristics Prevalence Ref
MSI/CIMP-H MSI Enriched for hypermutated tumours 30% [8]
CIN Epithelial 30%
Invasive Mesenchymal 40%
A-type MSI Hypermutated, dMMR
Good prognosis
22% [9]
B-type Epithelial MSS, BRAF WT, pMMR
High proliferative activity
Relatively poor baseline prognosis
Most benefit from adjuvant 
chemotherapy
62%
C-type Mesenchymal Undergone EMT
Low proliferative activity
Poor baseline prognosis
No benefit from adjuvant 
chemotherapy
16%
CCS1 Epithelial Mainly left sided
KRAS and TP53++
49% [10]
CCS2 MSI Mainly right sided
dMMR/MSI-H
24%
CCS3 Mesenchymal BRAF and KRAS++
Poor prognosis
Upregulation of genes involved in 
matrix remodelling and EMT
27%
C1: CIN 
immune  
down
Epithelial CIN+++
KRAS and TP53++
Immune system and EMT down 
regulated
21% [11]
C2: dMMR MSI dMMR/CIMP+++
BRAF++, KRAS++
Immune system and proliferation 
upregulated
19%
C3: KRAS 
mutated
Epithelial KRAS+++
Immune system and EMT down 
regulated
13%
C4: Cancer 
stem cell
Mesenchymal KRAS++
Proliferation down regulated
EMT upregulated
10%
C5: CIN Wnt up Epithelial CIN+++
KRAS and TP53++
Wnt pathway upregulated
27%
C6: CIN normal Mesenchymal CIN+++
Proliferation down regulated
EMT upregulated
10%
1.1 Mesenchymal Activation of MAPK, TGFβ and 
calcium signalling
19% [12]
1.2 MSI Activation of immune system-
related pathways
Highly enriched for MSI-H tumours
15%
1.3 Mesenchymal High expression of transporter genes 11%
2.1 Epithelial Activation of immune system-
related pathways
23%
2.2 Epithelial High expression of genes on 
chromosomes 13q and 20q
32%
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overlap of features between subgroups. Methodological differences in the processing 
and analysing of samples have also contributed to these inconsistencies.
In addition, the majority of samples from these datasets have been derived from 
primary tumours, so their applicability to advanced disease also needs to be con-
sidered as the molecular makeup of primary tumours versus metastases may vary, 
especially in response to the tumour microenvironment and immune cell infiltrate. 
Altogether, this has meant that the usefulness of these subclassification systems in 
clinical practice has been limited.
Subtype Major subtype 
category
Subtype characteristics Prevalence Ref
Surface crypt Epithelial KRAS+
Upregulated top colon crypt, 
secretory cell and metallothioneins
26% [13]
Lower crypt Epithelial Upregulated top colon crypt, 
proliferation, Wnt
Longest SAR
30%
CIMP-H MSI MSI+, BRAF+
Upregulated proliferation, immune, 
metallothioneins
Shortest SAR
11%
Mesenchymal Mesenchymal Upregulated EMT/stroma, CSC, 
immune
19%
Mixed Mesenchymal P53+
Upregulated EMT/stroma, immune, 
top colon crypt, Chr20q, CSC
14%
Inflammatory MSI Comparatively high expression of 
chemokines and interferon-related 
genes
Intermediate prognosis
18% [14]
Goblet Epithelial High mRNA expression of goblet-
specific MUC2 and TFF3, Good 
prognosis
May not benefit from adjuvant 
chemotherapy
14%
Enterocyte Epithelial High expression of enterocyte-
specific genes
Intermediate prognosis
18%
Cetuximab-
sensitive transit 
amplifying
Epithelial Higher levels of EGFR ligands 
known to predict cetuximab 
response
Good prognosis
32%
Cetuximab-
resistant transit 
amplifying
Overexpressed FLNA (regulates 
expression and signalling of cMET 
receptor), cell lines more sensitive to 
cMET inhibition
Good prognosis
Stem-like Mesenchymal High expression of Wnt signalling 
targets plus stem cell, myoepithelial 
and mesenchymal genes and low 
expression of differentiation markers
Worst prognosis
May benefit from adjuvant 
chemotherapy
Most benefit from FOLFIRI
18%
Table 2. 
Intrinsic molecular subtypes of CRC based on gene expression profiles.
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4. The consensus molecular subtypes of colorectal cancer
More recently, in order to resolve inconsistencies in subclassification systems 
and to aid clinical translation, the CRC research community formed an interna-
tional consortium dedicated to large-scale data sharing and analytics [22]. After 
analysing the independent transcriptomic-based classification systems (which 
comprised 18 CRC datasets and 4151 patients in total) and using unsupervised 
clustering techniques, four robust consensus molecular subtypes (CMSs) with dis-
tinguishing features were proposed. Tumours with mixed features (approximately 
13%) were thought to represent a transition phenotype or intratumoural heteroge-
neity. Table 3 summarises the main biological, molecular, clinical and prognostic 
associations of the four consensus subtypes.
In regard to genomic aberrations, CMS1 samples were hypermutated and 
encompassed the majority of MSI-H tumours. This group also displayed widespread 
hypermethylation and low prevalence of SCNAs. CMS2 and CMS4 subgroups dis-
played higher CIN via high SCNA counts. CMS3 samples consisted of fewer SCNAs 
than other CIN tumours, a significant proportion (30%) of hypermutated tumours 
CMS1
MSI immune
CMS2
Canonical
CMS3
Metabolic
CMS4
Mesenchymal
Percentage of 
samples
14 37 13 23
Biological 
characteristics
MSI high
CIMP high
Hypermutation
SCNA low
SCNA high Distinctive profile:
Mixed MSI status
SCNA low
CIMP low
SCNA high
Overexpression of 
proteins involved in 
DNA damage repair
Widespread 
hypermethylation 
status
Higher 
chromosomal 
instability
Intermediate 
levels of gene 
hypermethylation
Higher 
chromosomal 
instability
Molecular 
features
BRAF mutations
Activation of RTK 
and MAPK pathways
KRAS mutations
Activation of 
RTK and MAPK 
pathways
Immune infiltration 
and activation
Strong activation 
of immune evasion 
pathways
Wnt and Myc 
activation
Metabolic 
deregulation
Stromal 
infiltration
TGF-β 
activation
Angiogenesis
Clinical 
features
Females
Right sided tumours
Higher grade
Left sided 
tumours
More advanced 
stages
Prognostic 
features
Better relapse-free 
survival
Worse survival after 
relapse
Better 
survival after 
relapse
Worse relapse-
free and overall 
survival
Table 3. 
The four consensus molecular subtypes of CRC.
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and intermediate levels of gene hypermethylation [22]. Despite clear enrichment 
of certain gene mutations within CMS groups, such as high rates of BRAF mutation 
in CMS1 and KRAS mutations in CMS3, no single genetic aberration was found to 
be limited to one subtype, and no subtype was defined by a single molecular event. 
Further integrative genomic analysis did not draw any clear associations either, 
highlighting the poor genotype–phenotype correlation in this cancer.
Further exploration of gene expression data revealed insight into the underly-
ing biology of the subtypes: CMS1 samples showed strong immune activation and 
infiltration with CD4+ T helper cells, CD8+ cytotoxic T cells and natural killer (NK) 
cells along with strong activation of immune evasion pathways. CMS2 showed 
marked upregulation of Wnt and MYC downstream targets and higher expression 
of oncogenes EGFR, ERBB2, insulin-like growth factor 2 (IGF-2), insulin receptor 
substrate 2 (IRS-2) and transcription factor hepatocyte nuclear factor 4α (HNF4α). 
CMS3 samples showed enrichment for multiple metabolism signatures which are 
keeping with the described notion that activating KRAS mutations induce promi-
nent metabolic adaptation [23, 24]. CMS4 tumours showed upregulation of genes 
associated with epithelial-mesenchymal transition (EMT), such as transforming 
growth factor β (TGF-β) and integrins, as well as stromal invasion.
4.1 Clinical and prognostic associations of the consensus molecular subtypes
Associations between CMS subgroups and clinical features and prognosis were 
also investigated and showed that CMS1 tumours were more common in females, 
more likely to be right-sided and of higher histopathological grade. Conversely, 
CMS2 tumours were more likely to be left-sided and present at more advanced 
stages. CMS4 tumours show the worst OS and RFS even after adjustment for BRAF 
and KRAS mutations and MSI status. CMS1 tumours display good survival but very 
poor SAR in keeping with known data of MSI tumours associated with BRAFV600E 
mutations. CMS2 and CMS3 subgroups display intermediate survival, but a supe-
rior survival following relapse was noted in the CMS2 subgroup.
Further prognostic associations of the CMS subtypes have been explored via 
retrospective analysis of large clinical trial datasets, as have their association with 
biological therapies. 392 KRAS wild-type samples from the CALGB 80405 dataset 
were analysed via a NanoString platform to determine their CMS subtype classifica-
tion, and this was correlated with survival [25]. It was found that CMS1 tumours 
treated with bevacizumab had significantly longer OS compared to those treated with 
cetuximab. CMS2 tumours treated with bevacizumab had a trend towards shorter OS 
than those treated with cetuximab. A meta-analysis of six randomised trials, includ-
ing the CRYSTAL and FIRE-3 datasets, also confirmed the improvement in PFS and 
OS of left-sided tumours (CMS2) treated with anti-EGFR antibodies compared to no 
significant benefit for right-sided tumours (CMS1) [26]. No survival differences were 
found for left- or right-sided tumours treated with bevacizumab. This suggests sided-
ness of the primary tumour that determines efficacy of biological therapies, and this 
can possibly be explained by the biological differences of tumours from different sides 
of the bowel: left-sided tumours overexpress the EGFR ligands amphiregulin (AREG) 
and epiregulin (EREG) and also display amplifications of markers of cetuximab sensi-
tivity, whereas right-sided tumours show reduced expression of EGFR ligands [27].
4.2 Clinical utility of the consensus molecular subtypes
Much hope was placed upon the CMS classification system allowing stratifica-
tion of patients for clinical trials to validate the prognostic and predictive value of 
the subgroups and enable translation into clinical care. Although CMS classification 
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has enabled refinement of the large ‘non-MSI’ group of CRC patients and provided 
a tool for systemic interrogation, there is some data which suggests that critical 
clinical information which predicts for outcome is still not distinguishable under 
this classification system. For example, a separate analysis of the CALGB 80405 
dataset identified that sidedness of the primary tumour was still an independent 
prognostic factor over and above CMS subtype [28].
The association with treatment outcomes of the CMS subtypes, especially in the 
metastatic setting, still requires further exploration and validation. Kim et al. found 
that colorectal cancer assigner (CRCA) is subtyping more clearly defined oxalipla-
tin benefit group than CMS subtyping did prior to their analysis of the NSABP-C07 
trial [29]. It is also important to consider the 13% of samples which could not be 
classified into CMS subtypes and the need to better characterise samples of mixed 
phenotypes and the clinical implications of this.
The challenge of reproducibility of this classification system which requires com-
plex transcriptomic, proteomic and genomic analyses is also an issue, and its imple-
mentation is not feasible in many centres in its current form. There has been some work 
already undertaken to develop a robust and practical classifier based on immunohisto-
chemistry (IHC) which appears promising but requires prospective validation [30].
All in all, the clinical utility and widespread reproducibility of this classification 
system in CRC is still to be determined, and it is likely that, with further characteri-
sation, we may see additional subtyping of the four described subtypes in the future.
5. Conclusions
Much progress has been made in our understanding of the complex underly-
ing biology of CRC which leads to heterogeneous drug responses and outcomes. 
Comprehensive integrative molecular analysis has led to the identification of molecu-
larly distinct subgroups within this disease, and the consensus molecular subtypes have 
enabled some refinement of these subgroups. However, widespread reproducibility 
and confirmation of the clinical utility of CMS classification still need to be addressed. 
There are vast amounts of data being generated from molecular classification systems, 
and this needs to be prospectively integrated into clinical trial design in order to confirm 
biomarkers of resistance and response as well as to allow rational combinations of 
therapies to be explored. The ultimate goal is to streamline biomarker and drug codevel-
opment and recruit patients to innovative clinical trials of targeted agents to which they 
are more likely to respond based on the underlying molecular makeup of their tumours.
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